Results 141 to 150 of about 20,539 (229)

Validation of “Clinical Red Flags” for RA-ILD in an Italian cohort

Introduction Rheumatoid arthritis (RA) is a systemic inflammatory disease, characterized by articular and extra-articular manifestations, including Interstitial Lung Disease (ILD).
Chiocchi M., Cavalli F., Luciano A., Kroegler B., Bergamini A., Conigliaro P., Bonini C., Ora J., Chimenti M. S., Rogliani P., Cela E.   +10 more
core   +1 more source

Immune Complexes Shape the Pathogenicity of Autoantibodies in Systemic Autoimmune Diseases: Insights From an FcγRIIIA‐Reporter Assay

Arthritis &Rheumatology, Volume 78, Issue 11, Page 2365-2377, November 2026.
Objective Immune complexes (ICs), formed by autoantigen and autoantibody, play a pathogenic role in systemic autoimmune diseases through stimulation of Fcγ receptors (FcγR). However, studies investigating bioactivity of circulating ICs across various diseases remain limited.
Koji Suzuki, Masaru Takeshita, Yuki Imai, Hiroyuki Fukui, Kazunori Furuhashi, Kotaro Matsumoto, Jun Kikuchi, Keiko Yoshimoto, Yuko Kaneko   +8 more
wiley   +1 more source

Technical instrumentation R&D for ILD SiW ECAL large scale device

, 2018
Calorimeters with silicon detectors have many unique features and are proposed for several world-leading experiments. We describe the R&D program of the large scale detector element with up to 12 000 readout channels for the International Large Detector (
Balagura, V. (on behalf of SIW ECAL ILD collaboration)
core  

Lung Ultrasound for the Detection of Radiologic Progression of Interstitial Lung Abnormalities in Patients With Rheumatoid Arthritis

Arthritis &Rheumatology, Volume 78, Issue 11, Page 2221-2231, November 2026.
Objective Interstitial lung disease (ILD) is an important extra‐articular manifestation of rheumatoid arthritis (RA) associated with high mortality and morbidity. Lung ultrasonography (LUS) has recently emerged as a possible screening tool. We assessed the role of LUS in monitoring radiologic progression and the development of new interstitial lung ...
Marie Vermant, Valerie Van Ballaer, Joseph Jacob, Tine Follet, Ryoko Egashira, Kenny Anseele, Heleen Cypers, Laurens J. De Sadeleer, Nico De Crem, Tinne Goos, Barbara Neerinckx, Veerle Taelman, Nathalie Veyt, Alexandros Kalkanis, Patrick Verschueren, Wim A. Wuyts   +15 more
wiley   +1 more source

Expert Perspectives: Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis

Arthritis &Rheumatology, Volume 78, Issue 11, Page 2189-2202, November 2026.
Systemic sclerosis–associated interstitial lung disease (SSc‐ILD) is one of the leading causes of morbidity and mortality in SSc, affecting up to three‐quarters of patients. The disease course is highly heterogeneous, ranging from indolent, nonprogressive forms to rapidly progressive pulmonary fibrosis (PPF).
Devis Benfaremo, Dinesh Khanna, Corrado Campochiaro, Vincent Cottin, Fabrizio Luppi, Marco Matucci‐Cerinic, Gianluca Moroncini, Yannick Allanore   +7 more
wiley   +1 more source

Safety and pharmacokinetics of mosliciguat, a new, inhaled soluble guanylate cyclase activator, in healthy adult subjects

British Journal of Clinical Pharmacology, Volume 92, Issue 11, Page 4003-4016, November 2026.
Abstract Aim Mosliciguat (BAY 1237592), the first soluble guanylate cyclase (sGC) activator in a dry powder inhaler (DPI), could potentially treat pulmonary hypertension with a more targeted delivery than systemic sGC stimulators. We report safety and tolerability of mosliciguat in healthy men.
Johannes Nagelschmitz, Soundos Saleh, Sandra Ligges, Melanie Seidel‐Greven, Eva Becker‐Pelster, Sylvia M. Nikkho, Stefanie Boxnick, Wolfgang Timmer   +7 more
wiley   +1 more source

Research in progress: put the orphanage out of business.

, 2013
Paediatric interstitial lung disease (ILD) is rare and diverse, meaning no single centre will see sufficient children to perform the studies needed to make progress.
Nicholson AG, Gilbert C, Goldbeck L, Schwerk N, Epaud R, Griese M, Bush A1, ch ILD collaborators, BARBATO, ANGELO, Kronfeld K, Cunningham S, Clement A, Anthony G   +12 more
core  

Efficacy and Safety of Datopotamab Deruxtecan From a Single‐Institution Experience in Hormone Receptor–Positive, HER2‐Negative Metastatic Breast Cancer After Multiple Prior Therapies Including Antibody–Drug Conjugates

Cancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Background Datopotamab deruxtecan (Dato‐DXd) is a trophoblast cell surface antigen 2 (TROP2)–directed antibody–drug conjugate (ADC) with a topoisomerase I inhibitor payload and was approved by the Japan Pharmaceuticals and Medical Devices Agency in 2025 for patients with unresectable or recurrent hormone receptor–positive (HR+)/human epidermal
Hiroko Shimada, Maki Todo, Hiroshi Ishiguro, Emi Mikami, Wakako Inohana, Taeko Kurosawa, Ayako Nakame, Ayaka Sakakibara, Yuki Ichinose, Akihiro Fujimoto, Asami Nukui, Aya Asano, Hideki Yokogawa, Masahiro Ohara, Kazuo Matsuura, Takahiro Hasebe, Nobuko Fujiuchi, Akihiko Osaki, Toshiaki Saeki   +18 more
wiley   +1 more source

Real‐World Progression Patterns and Potential Prognostic Factors for Trastuzumab Deruxtecan‐Related Interstitial Lung Disease in Japanese Patients With Breast or Gastric Cancer

Cancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Background Interstitial lung disease (ILD)/pneumonitis is a safety concern with trastuzumab deruxtecan (T‐DXd). We characterized post‐onset changes in ILD severity and imaging patterns, and explored potential prognostic factors for fatal T‐DXd‐related ILD in Japanese patients with breast or gastric cancer.
Shinichi Sasaki, Katsunori Oikado, Tomohisa Baba, Masahiko Kusumoto, Yutaka Fujiwara, Masahiro Endo, Terufumi Kato, Yasuyuki Kurihara, Yoshinobu Saito, Kunihiro Yagihashi, Masafumi Sata, Yoshinao Sato, Hirotsugu Kenmotsu, Taiki Fukuda, Teppei Yamaguchi, Saiko Isshiki, Hiroshi Wakui, Haruki Kobayashi, Satoshi Ikeda, Motoyasu Kato, Ou Yamaguchi, Toshimi Takano, Ken Kato, Akiko Takenaka, Koji Hirata, Wataru Hashimoto, Kazuyoshi Kuwano   +26 more
wiley   +1 more source

Impacts of soybean breeding on shoot architecture

Crop Science, Volume 66, Issue 6, November/December 2026.
Abstract Despite decades of steady soybean (Glycine max (L.) Merr.) yield increases from improved cultivars, the accompanying changes in shoot architectural traits have been under‐researched. To address this, we analyzed 55 cultivars spanning eight decades of breeding and estimated a genetic gain for yield of 20.7 kg ha−1 year−1 in south‐central ...
Suma Sreekanta, Lovepreet Singh, Kamaldeep S. Virdi, Robert M. Stupar, Gary J. Muehlbauer, Aaron J. Lorenz   +5 more
wiley   +1 more source